Authors’ conclusions: the tetravalent vaccine against 4 meningococcal B antigens is associated with a relative risk reduction of 42% of cases of meningococcal B disease in children from 0 to 12 months of age in the United Kingdom (moderate GRADE evidence). Extrapolating this risk reduction to Spain's baseline risk, 19,729 children under one year of age should be vaccinated to avoid a case.
Reviewers’ commentary: the best evidence on the efficacy of the vaccine comes from a cohort study, which is consistent with the available information on immune response. The vaccine seems effective but its efficiency is not clear, therefore, we still need more information to document decision making. Considering the low incidence rate of invasive meningococcal disease, it is unlikely that this information will come from clinical trials, consequently, surveillance and cost-effectiveness studies should be considered.